<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931915</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-385/3-A</org_study_id>
    <nct_id>NCT03931915</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis</brief_title>
  <official_title>Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASKA Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASKA Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of TAK-385 40 mg orally administrated&#xD;
      once daily for 24 weeks compared with Leuprorelin [once/4 weeks, 3.75 or 1.88 mg&#xD;
      subcutaneously (SC)/time] in patients with endometriosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase III, multicenter, randomized, double-blind, parallel-group study to&#xD;
      investigate the efficacy and safety of TAK-385 40 mg once daily compared with leuprorelin&#xD;
      (once/4 weeks, 3.75 or 1.88 mg SC/time) in premenopausal subjects â‰¥ 20 years of age with&#xD;
      endometriosis. 320 women with endometriosis will be enrolled in the study. This study&#xD;
      consists of screening of approximately 1 to 6 weeks, run-in of approximately 3 to 6 weeks,&#xD;
      treatment of 24 weeks, and follow-up of 4 weeks. After signing the informed consent form,&#xD;
      subjects should record their symptoms in the electronic patient diary every day. During&#xD;
      run-in period, daily data will be collected in the electronic patient diary for calculation&#xD;
      of the baseline values for the efficacy evaluation.Following run-in period, subjects will&#xD;
      receive investigational products (TAK-385 + leuprorelin placebo or TAK-385 placebo +&#xD;
      leuprorelin) under double blind. During this study, subjects will visit the study center to&#xD;
      undergo the designated examinations and evaluations at each visit. Safety will be assessed&#xD;
      throughout the study by monitoring adverse events, vital signs, physical examinations,&#xD;
      clinical laboratory tests, 12-lead electrocardiograms (ECG), and assessments of bone mineral&#xD;
      density.Subjects will visit the study center to undergo the designated examinations and&#xD;
      evaluations at 28 days after final administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Actual">September 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of maximum Visual Analogue Scale (VAS) score for endometriosis associated pelvic pain</measure>
    <time_frame>Baseline and the last 28 days of treatment period</time_frame>
    <description>Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of mean VAS score for endometriosis associated pelvic pain</measure>
    <time_frame>Baseline and the last 28 days of treatment period</time_frame>
    <description>Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score for endometriosis associated pelvic pain</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS score for endometriosis associated pelvic pain</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
    <description>Pelvic pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score for menstrual pain</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Menstrual pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS score for menstrual pain</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
    <description>Menstrual pain will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score for endometriosis associated pelvic pain outside the menstruation period</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Pelvic pain outside the menstruation period will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS score for endometriosis associated pelvic pain outside the menstruation period</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
    <description>Pelvic pain outside the menstruation period will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score for dyspareunia</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Dyspareunia will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS score for dyspareunia</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
    <description>Dyspareunia will be assessed using the VAS (0 - 100) as pain evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of NTx (N-telopeptide)</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of BAP (Bone alkaline phosphatase)</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period from the last dose of study drug to return of menstrual cycles</measure>
    <time_frame>From Week 24 to Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>TAK-385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-385</intervention_name>
    <description>TAK-385 40 mg tablets + Leuprorelin acetate placebo injection</description>
    <arm_group_label>TAK-385</arm_group_label>
    <other_name>relugolix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin acetate</intervention_name>
    <description>TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection</description>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participant is a premenopausal Japanese woman aged 20 years or older at the time&#xD;
             consent is obtained.&#xD;
&#xD;
          2. The participant with endometriosis that falls under one of the following. However, in&#xD;
             case of recurrence after surgery, it must be diagnosed again by either of the&#xD;
             following.&#xD;
&#xD;
               -  The participant who has been diagnosed with endometriosis by Laparotomy or&#xD;
                  Laparoscopy.&#xD;
&#xD;
               -  The participant who has been confirmed ovarian chocolate cyst by Magnetic&#xD;
                  Resonance Imaging (MRI) or ultrasonic examination (vaginal, transabdominal or&#xD;
                  rectal).&#xD;
&#xD;
               -  The participant who has been diagnosed with clinical endometriosis and has the&#xD;
                  symptom of either induration of Douglas cavum, restriction of uterine mobility or&#xD;
                  pelvic tenderness confirmed by internal or rectal examination.&#xD;
&#xD;
          3. The participant must have dysmenorrhea or pelvic pain associated with endometriosis,&#xD;
             of which either 1 or both should be at least &quot;moderate&quot; as determined by the&#xD;
             investigator or subinvestigator using the B&amp;B scale.&#xD;
&#xD;
          4. The participant must have maximum VAS score &gt; 30 for pelvic pain associated with&#xD;
             endometriosis.&#xD;
&#xD;
          5. The participant has experienced regular menstrual cycles (25 to 38 days) that should&#xD;
             include menstrual bleeding of at least 3 consecutive days (at least 3 regular&#xD;
             menstrual cycles to be confirmed).&#xD;
&#xD;
          6. The participant agrees to use routinely adequate contraception from signing of&#xD;
             informed consent throughout the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant has the following drug usage:&#xD;
&#xD;
               -  Use of the following drugs within 24 weeks:bisphosphonate preparation or other&#xD;
                  investigational agent&#xD;
&#xD;
               -  Use of the following drugs within 16 weeks (for 1-, 3- and 6-month&#xD;
                  sustained-release preparations, within 20, 28 and 40 weeks, respectively):&#xD;
                  gonadotropin-releasing hormone (GnRH) analogues, danazol, or aromatase&#xD;
                  inhibitors.&#xD;
&#xD;
               -  Use of the following drugs within 8 weeks:dienogest, oral contraceptive or sex&#xD;
                  hormone preparations (norethindrone, norethisterone, medroxyprogesterone,&#xD;
                  estrogen, or other progestins, etc.)&#xD;
&#xD;
               -  Use of the following drugs (excluding drugs for external use and supplements)&#xD;
                  within 4 weeks :anti-coagulant drugs, anti-platelet drugs, tranexamic acid,&#xD;
                  selective estrogen receptor modulators, activated vitamin D preparations, other&#xD;
                  vitamin D preparations, calcitonin, ipriflavone, steroid hormones, vitamin K&#xD;
                  preparations, teriparatide, or denosumab&#xD;
&#xD;
          2. The participant has received TAK-385 (including placebo) in a previous clinical study.&#xD;
&#xD;
          3. The participant has ovarian chocolate cyst of 10 cm or more and over 40 years old at&#xD;
             the time imaging test is performed.&#xD;
&#xD;
          4. The participant has a history of panhysterectomy or bilateral oophorectomy.&#xD;
&#xD;
          5. The participant has had markedly abnormal uterine bleeding or anovulatory bleeding, as&#xD;
             determined by the investigator or subinvestigator.&#xD;
&#xD;
          6. The participant has nondiagnosable abnormal genital bleeding.&#xD;
&#xD;
          7. The participant has a current history of thyroid gland disorder with irregular&#xD;
             menstruation, or has a potential for irregular menstruation due to thyroid gland&#xD;
             disorder, as determined by the investigator or subinvestigator.&#xD;
&#xD;
          8. The participant has uterine fibroid requiring treatment.&#xD;
&#xD;
          9. The participant has lower abdominal pain due to irritable bowel syndrome or severe&#xD;
             interstitial cystitis.&#xD;
&#xD;
         10. The participant has a previous or current history of pelvic inflammatory disease&#xD;
             within 8 weeks.&#xD;
&#xD;
         11. The participant has a previous or current history of osteoporosis, osteopenia, or&#xD;
             other metabolic bone diseases.&#xD;
&#xD;
         12. The participant has a positive cervical cytology result [other than Negative for&#xD;
             Intraepithelial Lesion or Malignancy (NILM) in accordance with the 2014 Bethesda&#xD;
             system]. However, the following participant may participate in this study; Atypical&#xD;
             Squamous Cells of Undetermined Significance (ASC-US) and negative by high-risk Human&#xD;
             Papillomavirus (HPV) test. And furthermore, regarding the participant with negative&#xD;
             cervical cytology result conducted within 1 year, she may participate in this study&#xD;
             without additional test.&#xD;
&#xD;
         13. The participant has a malignant tumor or a history of a malignant tumor within 5&#xD;
             years.&#xD;
&#xD;
         14. The participant has clinically significant cardiovascular disease or uncontrollable&#xD;
             hypertension.&#xD;
&#xD;
         15. The participant is inappropriate for participation in this study based on 12-lead ECG&#xD;
             findings, as determined by the investigator or subinvestigator.&#xD;
&#xD;
         16. The participant has active liver disease or jaundice, or has Alanine aminotransferase&#xD;
             (ALT), Aspartate aminotransferase (AST) or total bilirubin &gt; 1.5 times the upper limit&#xD;
             of normal in the clinical laboratory tests.&#xD;
&#xD;
         17. The participant has previous or current history of diseases considered to be&#xD;
             inappropriate for participation in this study, including severe hepatic impairment,&#xD;
             jaundice, renal impairment, cardiovascular disease, endocrine system disease,&#xD;
             metabolic disorder, pulmonary disease, gastrointestinal disease, neural disease,&#xD;
             urological disease, immune disease, or mental disorder (especially depression-like&#xD;
             symptoms) or suicide attempt resulting from a mental disorder.&#xD;
&#xD;
         18. The participant has a previous or current history of hypersensitivity to GnRH&#xD;
             analogues, or has a previous or current history of severe hypersensitivity to other&#xD;
             drugs.&#xD;
&#xD;
         19. The participant is pregnant, lactating, or intending to become pregnant or to donate&#xD;
             ova between the signing date of informed consent and 1 month after the end of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chubu Rosai Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meitetsu Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiiku Ladies Clinic</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Aoba Municipal Hospital</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Bay Urayasu Ichikawa Medical Center</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsujinaka Hospital Kashiwanoha</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujito Clinic</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hashimoto Clinic</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshio Obstetrics Gynecology Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinsuma Hospital</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takamatsu Red Cross Hospital</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujisawa City Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinkan Clinic</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Kawasaki Saiwai Clinic</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tawada Ladies Clinic</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Medical Clinic</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chayamachi Ladies Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayakawa Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minami-Morimachi Ladies Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nomura Clinic Nanba</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikako Ladies Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanabe Ladies Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshimura Ladies Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dantsuka Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kashiwazaki Ladies Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maruyama Memorial General Hospital</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kusatsu General Hospital</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akasaka-Mitsuke Miyazaki Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginza Yoshida Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamada Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikebukuro Metroporitan Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NS Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sei Women's Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seijo Kinoshita Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimamura Memorial Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Women's Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokokura Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yukawa Women's Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Relugolix</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

